Background: Allogeneic hematopoietic stem cell (allo-HSC) transplantation is used in the
treatment of malignant hematological diseases. An important tool in monitoring post …

Relapse is a major complication of acute myeloid leukemia (AML) after allogeneic
hematopoietic stem cell transplantation (SCT). The objective of our study was to evaluate …

Jean Sanders and colleagues at the Fred Hutchinson Cancer Research Center reported in
1985 that sibling donor transplant in first remission is the optimal treatment for childhood …

BACKGROUND Chimerism and minimal residual disease (MRD) are suggested to be
prognostic for post-transplant relapses in AML patients. Nevertheless, the predictive values …

Background Allogeneic hematopoietic stem cell transplantation (allo-HSCT) remains the
only curative option for high-risk myeloid malignancies. Post-transplant cyclophosphamide …

Analysis of chimerism in blood post‐HCT using STR‐PCR is routinely applied in parallel
with quantification of MRD to predict relapse of leukemia. Real time quantitative PCR (RQ …

Objective: To determine the sensitivity and significance of B-cell chimerism for the detection
of early engraftment, transplant rejection, and disease relapse. Methods: The dynamic …

Relapse of acute myeloblastic leukemia (AML) after first allogenic hematopoietic stem-cell
transplantation (allo-HSCT) is a fatal complication. Sixty-five children transplanted for AML …

Haploidentical hematopoietic stem cell transplantation (HSCT) is a potentially curative
therapeutic regimen that could increase donor availability to nearly 100%. Rapid advances …

The origin of marrow and blood cells after hematopoietic cell transplantation (HCT) can be
identified by testing informative genetic markers that distinguish the donor and recipient …